Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126764271 | 12676427 | 1 | I | 20160811 | 20160823 | 20160823 | EXP | AU-ALEXION PHARMACEUTICALS INC-A201606018 | ALEXION | 25.00 | YR | M | Y | 0.00000 | 20160823 | OT | AU | AU |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126764271 | 12676427 | 1 | PS | SOLIRIS | ECULIZUMAB | 1 | Intravenous (not otherwise specified) | UNK | Y | 125166 | CONCENTRATE FOR SOLUTION FOR INFUSION | ||||||||
| 126764271 | 12676427 | 2 | SS | SOLIRIS | ECULIZUMAB | 1 | Intravenous (not otherwise specified) | 1200 MG, Q2W | Y | 125166 | 1200 | MG | CONCENTRATE FOR SOLUTION FOR INFUSION | QOW | |||||
| 126764271 | 12676427 | 3 | SS | SOLIRIS | ECULIZUMAB | 1 | Intravenous (not otherwise specified) | 1200 MG, Q2W | Y | 125166 | 1200 | MG | CONCENTRATE FOR SOLUTION FOR INFUSION | QOW | |||||
| 126764271 | 12676427 | 4 | SS | LABETALOL | LABETALOLLABETALOL HYDROCHLORIDE | 1 | Unknown | 200 MG, 2-3 TIMES DAILY | U | 0 | 200 | MG | |||||||
| 126764271 | 12676427 | 5 | SS | LERCANIDIPINE | LERCANIDIPINE | 1 | Unknown | 20 MG, QD | U | 0 | 20 | MG | QD | ||||||
| 126764271 | 12676427 | 6 | SS | RAMIPRIL. | RAMIPRIL | 1 | Unknown | 5 MG, QD | U | 0 | 5 | MG | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126764271 | 12676427 | 1 | Haemolytic uraemic syndrome |
| 126764271 | 12676427 | 4 | Malignant hypertension |
| 126764271 | 12676427 | 5 | Malignant hypertension |
| 126764271 | 12676427 | 6 | Malignant hypertension |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126764271 | 12676427 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126764271 | 12676427 | Blood creatinine increased | |
| 126764271 | 12676427 | Haemolytic uraemic syndrome | |
| 126764271 | 12676427 | Haptoglobin decreased | |
| 126764271 | 12676427 | Headache | |
| 126764271 | 12676427 | Lethargy | |
| 126764271 | 12676427 | Malignant hypertension | |
| 126764271 | 12676427 | Nausea | |
| 126764271 | 12676427 | Platelet count decreased | |
| 126764271 | 12676427 | Seizure |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |